Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02253550 · ClinicalTrials.gov registry record · Phase 2
Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection
A Phase 2 study, sponsored by Peter J. Ruane, M.D..
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT02253550 is a Phase 2 study that has completed, run by Peter J. Ruane, M.D.. The registered enrollment target is 30 participants.
The verdict
NCT02253550, a Phase 2 study, has completed, sponsored by Peter J. Ruane, M.D..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
Interventions
- DRUG Sofosbuvir
- DRUG Simeprevir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-10 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02253550
The ClinicalTrials.gov registry entry for NCT02253550 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Peter J. Ruane, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Sofosbuvir is the first listed.
NCT02253550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02253550 about?
NCT02253550 is a clinical study titled "Simeprevir in Combination With Sofosbuvir in Treatment-Naïve or -Experienced Adults With Chronic Genotype 4 Hepatitis C Virus Infection". This study will look at the safety and efficacy of 8 week and 12 week treatment with Sofosbuvir and Simeprevir in treatment-naïve and treatment-experienced patients with chronic hepatitis C genotype 4.
What is the current status of trial NCT02253550?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2014-10. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02253550?
The interventions under investigation include: Sofosbuvir (DRUG), Simeprevir (DRUG).
Who is sponsoring clinical trial NCT02253550?
This trial is sponsored by Peter J. Ruane, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.